soriasis(PSO)和特应性皮炎(AD)免疫发病症在典型上由2种不同的T细胞介导的反应驱动。In psoriasis, Th1/Th17 pathways mediated by interleukin (IL)-23/IL-17 cell-mediated signaling, while AD is marked by Th2/Th22 predominant humoral inflammatory response, eliciting IL-4, IL-13, and IL- 22.1 However, certain AD subtypes (eg, intrinsic, pediatric, Asian adults) demonstrate evidence of Th2, Th17, and Th22 co-expression, resulting in a more psoriasiform phenotype.2 Several cases have also been reported of exacerbations following “unilateral” suppression of this spectrum, with cases of paradoxical reactions in which patients with psoriasis develop eczematous eruptions after initiating anti-IL-17/IL-23 biologics and psoriasiform dermatitis after AD biologics.3-5这些示例支持潜在的PSO-AD光谱的想法。